Stock Ratings / Health Care / JANX / dividends

MLTX (46) CTY (61) HROW (71) MNKD (63) ⌘ Pro Terminal →

Janux Therapeutics Inc. (JANX) Dividend Safety Gauge & 10-Year DRIP Compounder

$17.83 -1.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.76

Janux Therapeutics Inc. (JANX) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.09B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $17.76 (-0.41%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JANX)Realized 20D OHLCV Swing Band: ±11.9%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY JANX SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 51.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$18.39-10.2% Next Q

Q2 (-2Q)

Grade E$16.51+0.9% Next Q

Q3 (-1Q)

Grade E$16.66+7% Next Q

Current

Grade E$17.83-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a JANX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While JANX currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.60) and Max Pain ($18.72) forces dealer call-delta covering toward $37.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JANX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “JANX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JANX)

✓Walkthrough of JANX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

JANX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.08%▲ ASCENDING CHANNEL

2026-10-30O $17.92H $18.17L $17.13C $17.83VOL 540.0K

RES: $22.82SUP: $16.41SMA50: $17.60SMA200: $15.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JANX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JANX Butterfly Map → + Track JANX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on JANX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JANX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for JANX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JANX)

Health Care Rank #862 of 1016 ⚔️ MLTX vs JANX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JANX vs. MLTX, CTY, HROW, MNKD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Janux Therapeutics Inc. (JANX) ranks #862 by composite RQD confidence (33/100, grade E) and #353 by equity capitalization ($1.09B). Within this direct 5-issuer industry benchmark cohort, JANX leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with JANX at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
JANX ACTIVE Janux Therapeutics Inc.	E	33/100	—	—	-13.8%	-1.22%	$1.09B	Benchmark Subject
MLTX MoonLake Immunotherapeutics (Class A)	D	46/100	—	—	-35.0%	+2.11%	$1.07B	/mltx-vs-janx →
CTY City Therapeutics Inc.	C-	61/100	—	—	—	+2.26%	$1.11B	/cty-vs-janx →
HROW Harrow Inc.	B-	71/100	—	75.1%	42.9%	+2.04%	$1.12B	/hrow-vs-janx →
MNKD MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	/mnkd-vs-janx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001817713

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Janux Therapeutics Inc. (JANX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$113.6M, operating cash flow of -$82.2M, and free cash flow of -$83.3M (-88.5% YoY). On the balance sheet, JANX closed FY2025 with $1.00B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$113.6M	-$82.2M	-$83.3M	$1.00B	—
FY2024 (FY)	2024-12-31	$0	-$69.0M	-$43.8M	-$44.2M	$1.06B	—
FY2023 (FY)	2023-12-31	$0	-$58.3M	-$50.6M	-$50.6M	—	—

3. JANX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JANX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Janux Therapeutics Inc. (NASDAQ: JANX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $17.83 (-1.22% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, JANX ranks #862 in composite RQD confidence.

How does JANX compare to MLTX and CTY in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JANX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, MLTX (MoonLake Immunotherapeutics (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CTY (City Therapeutics Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $1.11B). Among the 5-stock peer group, JANX leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JANX?

Per JANX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817713), Janux Therapeutics Inc. generated $0 in revenue, -$113.6M in net income, and -$83.3M in free cash flow against $1.00B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JANX trading relative to its 50-day, 200-day, and 52-week technical levels?

JANX last traded at $17.83 (-1.22% on volume of 905,885 shares), positioning the stock +1.31% above its 50-day simple moving average ($17.60) and +16.31% above its 200-day simple moving average ($15.33). Across its 52-week range of $12.12 to $35.34, JANX sits at the 24.6% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($15.71 to $19.95).

JANX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does JANX pay a dividend and is it safe?

Janux Therapeutics Inc. (JANX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: JANX RQD Cockpit JANX 12M Forecast JANX Earnings & Move JANX Dividends & DRIP JANX Insiders & 13F JANX Whale Options JANX Profit Sankey JANX News & Why